PT  - JOURNAL ARTICLE
AU  - Rada V. Moerman
AU  - Suzanne Arends
AU  - Petra M. Meiners
AU  - Arjan Vissink
AU  - Frederik K.L. Spijkervet
AU  - Frans G.M. Kroese
AU  - Elisabeth Brouwer
AU  - Hendrika Bootsma
TI  - Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome
AID  - 10.3899/jrheum.160459
DP  - 2017 Mar 01
TA  - The Journal of Rheumatology
PG  - 292--296
VI  - 44
IP  - 3
4099  - http://www.jrheum.org/content/44/3/292.short
4100  - http://www.jrheum.org/content/44/3/292.full
SO  - J Rheumatol2017 Mar 01; 44
AB  - Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjögren syndrome (pSS).Methods. Patients with pSS treated with RTX (n = 18) or ABA (n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level ≥ 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.